meta
|
evidence
oncology
Living systematic review and meta-analysis
locally advanced NSCLC - maintenance (M)
laNSCLC - M - all population
1
laNSCLC - M - EGFR mutant
HER inhibitor
EGFR inhibitor
erlotinib based treatment
erlotinib alone
immune chekpoint inhibitors
anti-PD-(L)1
durvalumab based treatment
durvalumab alone
sugemalimab based treatment
Sugemalimab
no study with result for this clinical condition